Cargando…

Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy

[Image: see text] Chemotherapy using natural compounds, such as resveratrol, curcumin, paclitaxel, docetaxel, etoposide, doxorubicin, and camptothecin, is of importance in cancer therapy because of the outstanding therapeutic activity and multitargeting capability of these compounds. However, poor s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashrafizadeh, Milad, Zarrabi, Ali, Hushmandi, Kiavash, Hashemi, Farid, Rahmani Moghadam, Ebrahim, Raei, Mehdi, Kalantari, Mahshad, Tavakol, Shima, Mohammadinejad, Reza, Najafi, Masoud, Tay, Franklin R., Makvandi, Pooyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015217/
https://www.ncbi.nlm.nih.gov/pubmed/33095554
http://dx.doi.org/10.1021/acscombsci.0c00099
_version_ 1783673636774739968
author Ashrafizadeh, Milad
Zarrabi, Ali
Hushmandi, Kiavash
Hashemi, Farid
Rahmani Moghadam, Ebrahim
Raei, Mehdi
Kalantari, Mahshad
Tavakol, Shima
Mohammadinejad, Reza
Najafi, Masoud
Tay, Franklin R.
Makvandi, Pooyan
author_facet Ashrafizadeh, Milad
Zarrabi, Ali
Hushmandi, Kiavash
Hashemi, Farid
Rahmani Moghadam, Ebrahim
Raei, Mehdi
Kalantari, Mahshad
Tavakol, Shima
Mohammadinejad, Reza
Najafi, Masoud
Tay, Franklin R.
Makvandi, Pooyan
author_sort Ashrafizadeh, Milad
collection PubMed
description [Image: see text] Chemotherapy using natural compounds, such as resveratrol, curcumin, paclitaxel, docetaxel, etoposide, doxorubicin, and camptothecin, is of importance in cancer therapy because of the outstanding therapeutic activity and multitargeting capability of these compounds. However, poor solubility and bioavailability of natural compounds have limited their efficacy in cancer therapy. To circumvent this hurdle, nanocarriers have been designed to improve the antitumor activity of the aforementioned compounds. Nevertheless, cancer treatment is still a challenge, demanding novel strategies. It is well-known that a combination of natural products and gene therapy is advantageous over monotherapy. Delivery of multiple therapeutic agents/small interfering RNA (siRNA) as a potent gene-editing tool in cancer therapy can maximize the synergistic effects against tumor cells. In the present review, co-delivery of natural compounds/siRNA using nanovehicles are highlighted to provide a backdrop for future research.
format Online
Article
Text
id pubmed-8015217
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-80152172021-04-02 Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy Ashrafizadeh, Milad Zarrabi, Ali Hushmandi, Kiavash Hashemi, Farid Rahmani Moghadam, Ebrahim Raei, Mehdi Kalantari, Mahshad Tavakol, Shima Mohammadinejad, Reza Najafi, Masoud Tay, Franklin R. Makvandi, Pooyan ACS Comb Sci [Image: see text] Chemotherapy using natural compounds, such as resveratrol, curcumin, paclitaxel, docetaxel, etoposide, doxorubicin, and camptothecin, is of importance in cancer therapy because of the outstanding therapeutic activity and multitargeting capability of these compounds. However, poor solubility and bioavailability of natural compounds have limited their efficacy in cancer therapy. To circumvent this hurdle, nanocarriers have been designed to improve the antitumor activity of the aforementioned compounds. Nevertheless, cancer treatment is still a challenge, demanding novel strategies. It is well-known that a combination of natural products and gene therapy is advantageous over monotherapy. Delivery of multiple therapeutic agents/small interfering RNA (siRNA) as a potent gene-editing tool in cancer therapy can maximize the synergistic effects against tumor cells. In the present review, co-delivery of natural compounds/siRNA using nanovehicles are highlighted to provide a backdrop for future research. American Chemical Society 2020-10-23 2020-12-14 /pmc/articles/PMC8015217/ /pubmed/33095554 http://dx.doi.org/10.1021/acscombsci.0c00099 Text en © 2020 American Chemical Society Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Ashrafizadeh, Milad
Zarrabi, Ali
Hushmandi, Kiavash
Hashemi, Farid
Rahmani Moghadam, Ebrahim
Raei, Mehdi
Kalantari, Mahshad
Tavakol, Shima
Mohammadinejad, Reza
Najafi, Masoud
Tay, Franklin R.
Makvandi, Pooyan
Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy
title Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy
title_full Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy
title_fullStr Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy
title_full_unstemmed Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy
title_short Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy
title_sort progress in natural compounds/sirna co-delivery employing nanovehicles for cancer therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015217/
https://www.ncbi.nlm.nih.gov/pubmed/33095554
http://dx.doi.org/10.1021/acscombsci.0c00099
work_keys_str_mv AT ashrafizadehmilad progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy
AT zarrabiali progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy
AT hushmandikiavash progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy
AT hashemifarid progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy
AT rahmanimoghadamebrahim progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy
AT raeimehdi progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy
AT kalantarimahshad progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy
AT tavakolshima progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy
AT mohammadinejadreza progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy
AT najafimasoud progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy
AT tayfranklinr progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy
AT makvandipooyan progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy